JP2017537928A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537928A5
JP2017537928A5 JP2017529817A JP2017529817A JP2017537928A5 JP 2017537928 A5 JP2017537928 A5 JP 2017537928A5 JP 2017529817 A JP2017529817 A JP 2017529817A JP 2017529817 A JP2017529817 A JP 2017529817A JP 2017537928 A5 JP2017537928 A5 JP 2017537928A5
Authority
JP
Japan
Prior art keywords
syringe
nominal volume
range
nominal
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017529817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537928A (ja
JP6726666B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/078482 external-priority patent/WO2016087569A1/en
Publication of JP2017537928A publication Critical patent/JP2017537928A/ja
Publication of JP2017537928A5 publication Critical patent/JP2017537928A5/ja
Application granted granted Critical
Publication of JP6726666B2 publication Critical patent/JP6726666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017529817A 2014-12-03 2015-12-03 免疫グロブリンを含む安定性が高められた医薬製品 Active JP6726666B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196069 2014-12-03
EP14196069.0 2014-12-03
PCT/EP2015/078482 WO2016087569A1 (en) 2014-12-03 2015-12-03 Pharmaceutical product with increased stability comprising immunoglobulins

Publications (3)

Publication Number Publication Date
JP2017537928A JP2017537928A (ja) 2017-12-21
JP2017537928A5 true JP2017537928A5 (enExample) 2018-12-27
JP6726666B2 JP6726666B2 (ja) 2020-07-22

Family

ID=52002817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529817A Active JP6726666B2 (ja) 2014-12-03 2015-12-03 免疫グロブリンを含む安定性が高められた医薬製品

Country Status (15)

Country Link
US (2) US12144861B2 (enExample)
EP (3) EP4450517A3 (enExample)
JP (1) JP6726666B2 (enExample)
KR (1) KR102745501B1 (enExample)
CN (2) CN121371151A (enExample)
AU (1) AU2015357068B2 (enExample)
BR (1) BR112017010442A2 (enExample)
CA (1) CA2968915A1 (enExample)
DK (2) DK3763384T3 (enExample)
ES (2) ES2988823T3 (enExample)
HU (2) HUE069126T2 (enExample)
MX (1) MX388043B (enExample)
PL (2) PL3763384T3 (enExample)
RU (1) RU2748841C2 (enExample)
WO (1) WO2016087569A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2788863C (en) 2010-02-04 2020-07-07 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) * 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
MX388858B (es) 2014-10-23 2025-03-20 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
MX388043B (es) 2014-12-03 2025-03-19 Csl Behring Ag Producto farmacéutico con estabilidad incrementada que comprende inmunoglobulinas.
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
TWI865430B (zh) * 2017-07-24 2024-12-11 美商再生元醫藥公司 穩定化之抗體組合物及其製法
AU2019274649B2 (en) * 2018-05-23 2025-10-09 Csl Behring Ag Treatment of CIDP
US12472162B2 (en) * 2018-07-24 2025-11-18 Carefusion 213, Llc Ready-to-use, terminally sterile packaging for surgical antiseptic and method of use
SI3659594T1 (sl) * 2018-11-30 2021-02-26 Klaus Stegemann Sterilna raztopina z aplikacijskim injektorjem, ki vsebuje medicinsko sredstvo in postopek z proizvodnjo le-te
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
BR112022001597A2 (pt) 2019-07-29 2022-03-22 Regeneron Pharma Embalagem de dispositivo médico e métodos relacionados
EP4400432A3 (en) * 2021-03-30 2024-09-18 SCHOTT Pharma Schweiz AG System for low-temperature storage of a pharmaceutical composi-tion, liquid composition, method and uses
WO2022216985A1 (en) * 2021-04-08 2022-10-13 Genixus, Corp. Syringe prefilled with pharmaceutical fluid
WO2023102398A2 (en) * 2021-11-30 2023-06-08 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof
USD1035436S1 (en) 2022-08-26 2024-07-16 Regeneron Pharmaceuticals, Inc. Packaging
USD1042107S1 (en) 2022-08-26 2024-09-17 Regeneron Pharmaceuticals, Inc. Packaging
USD1047700S1 (en) 2022-08-26 2024-10-22 Regeneron Pharmaceuticals, Inc. Packaging
EP4689667A1 (en) 2023-03-29 2026-02-11 CSL Behring AG Methods of identifying immunoglobulin associated with adverse reactions

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364792A1 (de) 1973-01-15 1974-07-18 South African Inventions Verfahren zum reinigen von gammaglobulin
JPS5420124A (en) 1977-07-14 1979-02-15 Green Cross Corp:The Preparation of gamma-globulin intravenous injection
US4186192A (en) 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
JPS5731623A (en) 1980-07-30 1982-02-20 Morishita Seiyaku Kk Production of gamma-globulin for intravenous injection
JPS56127321A (en) 1980-03-10 1981-10-06 Mochida Pharmaceut Co Ltd Preparation of gamma-globulin pharmaceutical
JPS56135418A (en) 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JPS57128635A (en) 1981-01-30 1982-08-10 Morishita Seiyaku Kk Pharmaceutical preparation of gamma-globulin for venoclysis
US4360451A (en) 1981-08-10 1982-11-23 Basf Wyandotte Corporation Amphoteric surfactant gels
US4396608A (en) 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4439421A (en) 1982-08-30 1984-03-27 Baxter Travenol Laboratories, Inc. Stabilized gamma globulin concentrate
JPS6042336A (ja) 1983-08-18 1985-03-06 Nippon Seiyaku Kk 免疫グロブリンの製造方法
JPS60120823A (ja) 1983-12-02 1985-06-28 Green Cross Corp:The IgG単量体
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPH0825902B2 (ja) 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
GB8628104D0 (en) 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
DE3641115A1 (de) 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
EP0392717A1 (en) 1989-04-04 1990-10-17 Eli Lilly And Company Pharmaceutical formulations containing immunoglobulin conjugates
JPH0341033A (ja) 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
DK0447585T4 (da) 1990-03-22 2003-09-01 Biotest Pharma Gmbh Fremgangsmåde til fremstilling af et intravenøst tolerant immunglobulin-G-præparat
JPH04346934A (ja) 1991-05-24 1992-12-02 Green Cross Corp:The γ−グロブリンの液状製剤
DE4118912C1 (enExample) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP2942412B2 (ja) 1991-12-26 1999-08-30 鐘紡株式会社 化粧料
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
DE59309332D1 (de) 1993-12-27 1999-03-04 Rotkreuzstiftung Zentratrallab Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält
JPH07238036A (ja) 1994-02-28 1995-09-12 Green Cross Corp:The 静注用グロブリン液状組成物のグロブリン二量体増加抑制方法
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3765108B2 (ja) 1994-09-30 2006-04-12 三菱ウェルファーマ株式会社 静脈注射用グロブリン製剤
CA2205138A1 (en) 1994-11-16 1996-05-23 Baxter International Inc. Human antibodies to t-cell receptor peptides and methods for their preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
KR101042660B1 (ko) 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 안정한 액체 인터페론 제제
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
PT911037E (pt) 1997-10-23 2002-12-31 Mitsubishi Pharma Corp Preparacao de imunoglobulina armazenavel a temperatura ambiente para injeccao intravenosa
US6162904A (en) 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
ES2229784T3 (es) 1998-06-09 2005-04-16 Statens Serum Institut Proceso de produccion de inmunoglobulinas para administracion intravenosa y otros productos de inmunoglobulina.
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AT410637B (de) * 2001-06-01 2003-06-25 Igeneon Krebs Immuntherapie Verwendung von polyklonalen immunglobulinen
CA2465436A1 (en) 2001-11-02 2003-05-15 Meridian Medical Technologies, Inc. A medicament container, a medicament dispensing kit for administering medication and a method for packaging the same
US20050276823A1 (en) 2002-07-12 2005-12-15 Cini John K Methods and compositions for preventing oxidative degradation of proteins
US20050142139A1 (en) 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
US20050075611A1 (en) * 2003-10-01 2005-04-07 Hetzler Kevin G. Low extractable, thermoplastic syringe and tip cap
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20060076536A1 (en) * 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
EP1767347A1 (de) * 2005-09-27 2007-03-28 Alcan Technology & Management Ltd. Deckfolie für Blisterverpackungen
US8852167B2 (en) 2005-12-01 2014-10-07 Bayer Medical Care Inc. Medical connector
KR20090060453A (ko) 2006-09-25 2009-06-12 메디뮨 엘엘씨 안정화된 항체 제제 및 그것의 용도
GB0619060D0 (en) 2006-09-27 2006-11-08 Glaxosmithkline Biolog Sa Novel process
SG10201402265YA (en) * 2008-02-07 2014-08-28 Amgen Inc Stabilized protein compositions
GB2471726B (en) * 2009-07-10 2013-09-11 Oval Medical Technologies Ltd A pre-filled syringe including an oxygen absorber
HRP20160530T1 (hr) 2009-09-17 2016-07-29 Baxalta Incorporated Stabilna ko-formulacija hijaluronidaze i imunoglobulina, te postupci njezine uporabe
EA031209B9 (ru) 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
CA2788863C (en) 2010-02-04 2020-07-07 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) * 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
US10040855B2 (en) * 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
FR2995213A1 (fr) * 2012-09-12 2014-03-14 Lfb Biotechnologies Seringue contenant une composition, notamment pharmaceutique, comprenant des immunoglobulines, son procede de fabrication et son utilisation
AU2014230834B9 (en) * 2013-03-14 2017-08-31 Fresenius Kabi Deutschland Gmbh Injectable morphine formulations
US9248229B2 (en) * 2013-03-14 2016-02-02 Becton, Dickinson France S.A.S. Packaging system for oxygen-sensitive drugs
JP6612763B2 (ja) * 2014-10-02 2019-11-27 テルモ株式会社 タンパク質溶液製剤を収容するための医療用容器
MX388043B (es) 2014-12-03 2025-03-19 Csl Behring Ag Producto farmacéutico con estabilidad incrementada que comprende inmunoglobulinas.

Similar Documents

Publication Publication Date Title
JP2017537928A5 (enExample)
JP2016065085A5 (enExample)
JP2016027901A5 (enExample)
JP2015053053A5 (enExample)
EA201790630A1 (ru) Способы получения рибозидов
WO2015153889A3 (en) Materials and methods for the treatment of latent viral infection
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
WO2016011222A3 (en) Circular polynucleotides
EA201691991A1 (ru) Мультиспецифические антитела
JP2016502162A5 (enExample)
JP2014237817A5 (enExample)
IL247111A0 (en) Preventive or therapeutic agent for kidney disease
TWD173737S (zh) 肌肉鍛鍊機器
JP2018533683A5 (enExample)
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
FR3041503B1 (fr) Projectiles oxodegradables contenant des pheromones
JP2015186128A5 (enExample)
JP2016540026A5 (enExample)
JP2015173751A5 (enExample)
WO2015138532A3 (en) Methods for the treatment of kidney fibrosis
JP2016540019A5 (enExample)
JP2016038993A5 (enExample)
JP2015016294A5 (enExample)
UY4430S (es) “motocicleta”.
IL257940A (en) Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof